Suppr超能文献

CCR5-Δ32和CCR2-64I等位基因对HIV-1疾病进展的影响:保护作用随感染持续时间而变化。

Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection.

作者信息

Mulherin Stephanie A, O'Brien Thomas R, Ioannidis John P, Goedert James J, Buchbinder Susan P, Coutinho Roel A, Jamieson Beth D, Meyer Laurence, Michael Nelson L, Pantaleo Giuseppe, Rizzardi G Paolo, Schuitemaker Hanneke, Sheppard Haynes W, Theodorou Ioannis D, Vlahov David, Rosenberg Philip S

机构信息

Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH/DHHS, 6120 Executive Boulevard, Rockville, MD 20852, USA.

出版信息

AIDS. 2003 Feb 14;17(3):377-87. doi: 10.1097/01.aids.0000050783.28043.3e.

Abstract

OBJECTIVE

To examine temporal variation in the effects of CCR5-Delta32 and CCR2-64I chemokine receptor gene polymorphisms on HIV-1 disease progression.

DESIGN

Pooled analysis of individual patient data from 10 cohorts of HIV-1 seroconverters from the United States, Europe, and Australia.

METHODS

We studied HIV-1 seroconverters of European (n = 1635) or African (n = 215) ancestry who had been genotyped for CCR5-Delta32 and CCR2-64I. We used Cox proportional hazards models with time-varying coefficients to determine whether the genetic protection against AIDS (1987 case definition) and death varied with time since seroconversion.

RESULTS

Protection against AIDS conferred by CCR5-Delta32 held constant at a 31% (RH 0.69, 95% CI 0.54, 0.88) reduction in risk over the course of HIV-1 infection, whereas protection against death held constant at a 39% reduction in risk (RH 0.61, 95% CI 0.45, 0.88). When the period from AIDS to death was isolated, the survival benefit of CCR5-Delta32 diminished 2 years after AIDS. Protection against AIDS conferred by CCR2-64I was greatest early in the disease course. Compared with individuals without CCR5-Delta32 or CCR2-64I, individuals with one or two copies of CCR2-64I had a 58% lower risk of AIDS during the first 4 years after seroconversion (RH 0.42, 95% CI 0.23, 0.76), a 19% lower risk during the subsequent 4 years (RH 0.81, 95% CI 0.59, 1.12), and no significant protection thereafter.

CONCLUSION

The protection against AIDS provided by CCR5-Delta32 is continuous during the course of infection. In contrast, the protection provided by CCR2-64I is greatest early in the course of infection.

摘要

目的

研究CCR5 - Δ32和CCR2 - 64I趋化因子受体基因多态性对HIV - 1疾病进展影响的时间变化。

设计

对来自美国、欧洲和澳大利亚的10个HIV - 1血清转化者队列的个体患者数据进行汇总分析。

方法

我们研究了欧洲血统(n = 1635)或非洲血统(n = 215)的HIV - 1血清转化者,这些人已对CCR5 - Δ32和CCR2 - 64I进行了基因分型。我们使用具有时变系数的Cox比例风险模型来确定针对艾滋病(1987年病例定义)和死亡的基因保护是否随血清转化后的时间而变化。

结果

在HIV - 1感染过程中,CCR5 - Δ32对艾滋病的保护作用保持恒定,风险降低31%(相对风险0.69,95%置信区间0.54,0.88),而对死亡的保护作用保持恒定,风险降低39%(相对风险0.61,95%置信区间0.45,0.88)。当将从艾滋病到死亡的时间段单独分离出来时,CCR5 - Δ32的生存益处在艾滋病发生2年后减弱。CCR2 - 64I对艾滋病的保护作用在疾病进程早期最大。与没有CCR5 - Δ32或CCR2 - 64I的个体相比,具有一份或两份CCR2 - 64I拷贝的个体在血清转化后的前4年患艾滋病的风险降低58%(相对风险0.42,95%置信区间0.23,0.76),在随后的4年中风险降低19%(相对风险0.81,9%置信区间0.59,1.12),此后无显著保护作用。

结论

CCR5 - Δ32在感染过程中对艾滋病的保护作用是持续的。相比之下,CCR2 - 64I在感染过程早期提供的保护作用最大。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验